The U.S. Food and Drug Administration (FDA) has granted fast-track approval for Eli Lilly's new weight-loss pill, orforglipron, which will be marketed under the brand name Foundayo. This oral medication is designed to assist individuals in managing obesity and related health conditions. It belongs to the GLP-1 drug class, which mimics a natural hormone that helps regulate appetite and induces feelings of fullness. The pill is expected to be available starting next week, with costs for patients ranging from $25 per month for those with insurance to between $149 and $349 depending on the dosage. Clinical trials involving over 3,000 adults demonstrated that patients taking the highest dose lost an average of 11.2% of their body weight over 16 months, compared to modest reductions in those receiving a placebo. While the convenience of an oral pill is a significant advantage over injectable treatments, it may lead to less weight loss than options like Zepbound and Wegovy. Nevertheless, users showed improvements in blood pressure, cholesterol, and other health markers. Some participants experienced side effects, primarily gastrointestinal issues, resulting in a small number discontinuing treatment. Experts believe this approval could enhance access to obesity treatments, especially for those who cannot afford or prefer not to use injectable drugs.